1. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 2002, 1,
13–25.
2. Mahy, B. W. J. An overview on the use of a viral pathogen as a bioterrorism agent: why
smallpox? Antiviral Res. 2003, 57, 1–5.
3. Baker, R. O.; Bray, M.; Huggins, J. W. Potential antiviral therapeutics for smallpox,
monkeypox and other orthopoxvirus infections. Antiviral Res. 2003, 57, 13–23.
4. Smee, D. F.; Sidwell, R.W. A review of compounds exhibiting anti-orthopoxvirus activity
in animal models. Antiviral Res. 2003, 57, 41–52.
5. Neyts, J.; De Clercq, E. Therapy and short-term prophylaxis of poxvirus infections:
historical background and perspectives. Antiviral Res. 2003, 57, 25–33.
6. De Clercq, E.; Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against
poxvirus infections. Rev. Med. Virol. 2004, 14, 289–300.
7. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55,
1–13.
8. Neyts, J.; De Clercq, E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-
cytosine for the treatment of lethal vaccinia virus infections in severe combined immune
deficiency (SCID) mice. J. Med. Virol. 1993, 41, 242–246.
9. Huggins, J.W.; Martinez, M. J.; Hartmann, C. J.; Hensley, L. E.; Jackson, D. L.; Kefauver,
D. F.; Kulesh, D. A.; Larsen, T.; Miller, D. M.; Mucker, E. M.; Shamblin, J. D.; Tate, M.
K.; Whitehouse, C. A.; Zwiers, S. H; Jahrling, P. B. Successful cidofovir treatment of
smallpox-like disease in variola and monkeypox primate models. Abstracts of the 17th
International Conference on Antiviral Research, Tucson, AZ, USA, 2–6 May 2004.
Antiviral Res. 2004, 62, A57, no. 76.
10. Evans, D. H.; Magee, W.; Hostetler, K. Y. Inhibition of orthopoxvirus DNA polymerases
by cidofovir diphosphate: in vitro enzymatic studies using highly purified vaccinia virus
DNA polymerase. Abstracts of the 17th International Conference on Antiviral Research,
Tucson, AZ, USA, 2–6 May 2004. Antiviral Res. 2004, 62, A57, no. 74.
11. Andrei, G.; Holy´ , A.; Fiten, P.; Opdenakker, G.; De Clercq, E.; Snoeck, R. Isolation of
vaccinia virus (VV) mutants resistant to different acyclic nucleoside phosphonate
analogues (ANPs). Abstracts of the 17th International Conference on Antiviral Research,
Tucson, AZ, USA, 2–6 May 2004. Antiviral Res. 2004, 62, A72, no. 111.
12. Smee, D. F.; Bailey, K. W.; Holy´ , A.; Sidwell, R. W. A cidofovir-resistant form of the
highly virulent WR strain of vaccinia virus is cross-resistant to related antiviral agents and
is highly attenuated for virulence in mice. Abstracts of the 17th International Conference
on Antiviral Research, Tucson, AZ, USA, 2–6 May 2004. Antiviral Res. 2004, 62, A57,
no. 75.
13. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K.
Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of
cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991–995.
14. Aldern, K. A.; Ciesla, S. L.;Winegarden, K. L.; Hostetler, K. Y. Increased antiviral activity
of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is
explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63, 678–681.
15. Neyts, J.; Leyssen, P.; Verbeken, E.; De Clercq, E. Efficacy of cidofovir in a murine
model for disseminated/progressive vaccinia. Antimicrob. Agents Chemother. 2004, 48,
2267–2273.
16. Gritsun, T. S.; Lashkevich, V. A.; Gould, E. A. Tick-borne encephalitis. Antiviral Res.
2003, 57, 129–146.
17. Leyssen, P.; Charlier, N.; Paeshuyse, J.; De Clercq, E.; Neyts, J. Prospects for antiviral
therapy. Adv. Virus Res. 2003, 61, 511–553.
18. Leyssen, P.; Croes, R.; Rau, P.; Heiland, S.; Verbeken, E.; Sciot, R.; Paeshuyse, J.;
Charlier, N.; De Clercq, E.; Meyding-Lamade´, U.; Neyts, J. Acute encephalitis, a
poliomyelitis-like syndrome and neurological sequelae in a hamster model for flavivirus
infections. Brain Pathol. 2003, 13, 279–290.
19. Leyssen, P.; Drosten, C.; Paning, M.; Charlier, N.; Paeshuyse, J.; De Clercq, E.; Neyts, J.
Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced
encephalitis in mice. Antimicrob. Agents Chemother. 2003, 47, 777–782.
20. Neyts, J.; Meerbach, A.; McKenna, P.; De Clercq, E. Use of the yellow fever virus vaccine
strain 17D for the study of strategies for the treatment of yellow fever virus infections.
Antiviral Res. 1996, 30, 125–132.
21. Morrey, J. D.; Smee, D. F.; Sidwell, R. W.; Tseng, C. Identification of active antiviral
compounds against a New York isolate of West Nile virus. Antiviral Res. 2002, 55,
107–116.
22. Iversen, P. L.; Stein, D.; Kroeker, A.; Arora, V.; Barklis, E., Hill, A.; Smith, A.;Wallace,
R. Rapid development of an antisense phosphorodiamidate morpholino oligomer for
the treatment of West Nile virus. Abstracts of the 17th International Conference
on Antiviral Research, Tucson, AZ, USA, 2–6 May 2004. Antiviral Res. 2004, 62,
A32, no. 15.
23. Charrel, R. N.; de Lamballerie, X. Arenaviruses other than Lassa virus. Antiviral Res.
2003, 57, 89–100.
24. Drosten, C.; Ku¨mmerer, B. M.; Schmitz, H.; Gu¨nther, S. Molecular diagnostics of viral
hemorrhagic fevers. Antiviral Res. 2003, 57, 61–87.
25. Andrei, G.; De Clercq, E. Inhibitory effect of selected antiviral compounds on arenavirus
replication in vitro. Antiviral Res. 1990, 14, 287–300.
